Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum
    Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum
    • News

  • SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    • News

  • Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    • News

  • Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    • News

  • Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    • News

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

Fund Manager thoughts on a COVID-19 vaccine and near-term outlook

  • In Opinion
  • September 18, 2020
  • Zach Riaz
Fund Manager thoughts on a COVID-19 vaccine and near-term outlook

BanyanTree Investment Group was recently featured on Ausbiz where Fund Manager Zach Riaz offered his views on the recent market correction and the periphery services that will see increased commercial activity once a COVID-19 vaccine is developed. Here are this thoughts.

Vaccine timeline

Clearly this will have a material impact on investor sentiment, the health outcome is another conversation. University of Oxford/AstraZeneca is the horse that most are backing, which makes up approximately 35% of total pre-ordered doses globally.

4 major vaccines are expected to begin mass production before the end of 2020 – including AstraZeneca, Sinopharm (China), Pfizer (EU/US). Apart from this the ability to distribute the vaccine will be logistical effort – International Air Transport Association / DHL estimates 8,000 747 cargo aircrafts / 15,000 flights are required to deliver doses to the masses. And that is one dose – most vaccines in development will require two. Further, they need to be delivered under certain conditions – temperature requirements.


U.S. markets have downside risks

The U.S. markets are at a peculiar crossroads – U.S. elections and U.S. fiscal cliff represent meaningful downside risks. History suggests markets have traded lower in and around U.S. elections more often than not. From a tactical asset allocation perspective investors could mount a reasonable argument to be tactically underweight the U.S. market.

There is still no agreement on the new stimulus package in the U.S. and we hear that there is the possibility of a no stimulus deal until after the election (this could ofcourse be just political grandstanding). Despite all the central bank liquidity, this is a real issue given markets have become so use to fiscal sugar hits and even U.S. Fed Chair Jerome Powell noted that fiscal policies were required to stop the economy from stalling.

Whilst previously the Republicans were happy to consider $1 – 1.5 trillion dollars in further stimulus measures, they now want to pull this figure lower given the strength in the economic data.


Europe

Hard Brexit concerns are starting to reemerge, although this is more a UK issue versus a broader Euro issue.

 

This update was provided by BanyanTree Investment Group.

  • About
  • Latest Posts
Zach Riaz
Investment Manager / Director at BanyanTree Investment Group
Latest posts by Zach Riaz (see all)
  • Quick Update: Who bought the dip?Iron ore update + more - August 14, 2024
  • What if we are NOT in a new “commodities supercycle”? - August 1, 2024
  • Who is going to power the AI boom? - May 30, 2024
  •  
  •  
  •  
  •  
  • covid vaccine
  • zach riaz
  • Opinion

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Zach Riaz
Investment Manager / Director at BanyanTree Investment Group
Latest posts by Zach Riaz (see all)
  • Quick Update: Who bought the dip?Iron ore update + more - August 14, 2024
  • What if we are NOT in a new “commodities supercycle”? - August 1, 2024
  • Who is going to power the AI boom? - May 30, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Zach Riaz
Investment Manager / Director at BanyanTree Investment Group
Latest posts by Zach Riaz (see all)
  • Quick Update: Who bought the dip?Iron ore update + more - August 14, 2024
  • What if we are NOT in a new “commodities supercycle”? - August 1, 2024
  • Who is going to power the AI boom? - May 30, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.